Investigating new drugs for Alzheimer's disease targeting a specific brain receptor

Subtype-selective NMDA ligands for Alzheimer's Disease

NIH-funded research Emory University · NIH-11075243

This study is working on a new imaging tool to help us see how a specific part of the brain related to Alzheimer's disease works, which could lead to better treatments for patients.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionEmory University NIH-funded
Lab location1 site (Atlanta, United States)
Project IDNIH-11075243 on NIH RePORTER

What this research studies

This research focuses on developing a novel PET ligand that targets the GluN2B subunit of the N-Methyl-D-aspartic acid receptor, which is crucial in understanding and treating Alzheimer's disease and related dementias. By using advanced imaging techniques, the study aims to quantify the distribution and engagement of this receptor in living brains, providing insights that were previously unattainable. The goal is to create a more effective therapeutic approach by improving drug discovery processes for Alzheimer's treatments. Patients may benefit from enhanced understanding and potential new therapies targeting this specific receptor.

Who could benefit from this research

Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or related dementias.

Not a fit: Patients with other forms of dementia not related to Alzheimer's may not receive benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to more effective treatments for Alzheimer's disease, improving patient outcomes and quality of life.

How similar studies have performed: While there have been attempts to target the GluN2B subunit, this specific approach using a novel PET ligand is relatively untested and aims to overcome previous limitations.

Where this research is happening

Atlanta, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Alzheimer disease dementiaAlzheimer syndromeAlzheimer's Disease
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.